Get started
ADVERUM BIOTECHNOLOGIES INC USD0.0001ADVERUM BIOTECHNOLOGIES INC USD0.0001ADVERUM BIOTECHNOLOGIES INC USD0.0001

ADVERUM BIOTECHNOLOGIES INC USD0.0001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0HA3 chart


Full chart

0HA3 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪128.35 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−6.05 USD
Net income (FY)
‪−117.17 M‬ USD
Revenue (FY)
‪3.60 M‬ USD
Shares float
‪12.25 M‬
Beta (1Y)
1.14

Employees


Employees (FY)
121
Change (1Y)
−2 −1.63%
Revenue / Employee (1Y)
‪29.75 K‬ USD
Net income / Employee (1Y)
‪−968.31 K‬ USD

About Adverum Biotechnologies, Inc.


Sector
Health Technology
CEO
Laurent Fischer
Headquarters
Redwood City
Website
adverum.com
Founded
2006
FIGI
BBG00JRY9L53
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0HA3 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0HA3 is 6.10 USD — it has decreased by −2.94% in the past 24 hours. Watch ADVERUM BIOTECHNOLOGIES INC USD0.0001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ADVERUM BIOTECHNOLOGIES INC USD0.0001 stocks are traded under the ticker 0HA3.
0HA3 stock has fallen by −20.33% compared to the previous week, the month change is a −25.43% fall, over the last year ADVERUM BIOTECHNOLOGIES INC USD0.0001 has showed a −92.82% decrease.
We've gathered analysts' opinions on ADVERUM BIOTECHNOLOGIES INC USD0.0001 future price: according to them, 0HA3 price has a max estimate of 40.00 USD and a min estimate of 10.00 USD. Watch 0HA3 chart and read a more detailed ADVERUM BIOTECHNOLOGIES INC USD0.0001 stock forecast: see what analysts think of ADVERUM BIOTECHNOLOGIES INC USD0.0001 and suggest that you do with its stocks.
0HA3 reached its all-time high on Mar 15, 2024 with the price of 18,480.00 USD, and its all-time low was 6.45 USD and was reached on Aug 5, 2024. View more price dynamics on 0HA3 chart.
See other stocks reaching their highest and lowest prices.
0HA3 stock is 3.17% volatile and has beta coefficient of 1.14. Track ADVERUM BIOTECHNOLOGIES INC USD0.0001 stock price on the chart and check out the list of the most volatile stocks — is ADVERUM BIOTECHNOLOGIES INC USD0.0001 there?
Today ADVERUM BIOTECHNOLOGIES INC USD0.0001 has the market capitalization of ‪128.35 M‬, it has decreased by −14.90% over the last week.
Yes, you can track ADVERUM BIOTECHNOLOGIES INC USD0.0001 financials in yearly and quarterly reports right on TradingView.
ADVERUM BIOTECHNOLOGIES INC USD0.0001 is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
0HA3 earnings for the last quarter are −1.30 USD per share, whereas the estimation was −1.31 USD resulting in a 0.55% surprise. The estimated earnings for the next quarter are −1.36 USD per share. See more details about ADVERUM BIOTECHNOLOGIES INC USD0.0001 earnings.
ADVERUM BIOTECHNOLOGIES INC USD0.0001 revenue for the last quarter amounts to ‪1.00 M‬ USD, despite the estimated figure of ‪125.00 K‬ USD. In the next quarter, revenue is expected to reach 0.00 USD.
0HA3 net income for the last quarter is ‪−27.13 M‬ USD, while the quarter before that showed ‪−18.48 M‬ USD of net income which accounts for −46.86% change. Track more ADVERUM BIOTECHNOLOGIES INC USD0.0001 financial stats to get the full picture.
No, 0HA3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 121.00 employees. See our rating of the largest employees — is ADVERUM BIOTECHNOLOGIES INC USD0.0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADVERUM BIOTECHNOLOGIES INC USD0.0001 EBITDA is ‪−110.05 M‬ USD, and current EBITDA margin is ‪−3.28 K‬%. See more stats in ADVERUM BIOTECHNOLOGIES INC USD0.0001 financial statements.
Like other stocks, 0HA3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADVERUM BIOTECHNOLOGIES INC USD0.0001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADVERUM BIOTECHNOLOGIES INC USD0.0001 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADVERUM BIOTECHNOLOGIES INC USD0.0001 stock shows the sell signal. See more of ADVERUM BIOTECHNOLOGIES INC USD0.0001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.